HOME >> MEDICINE >> NEWS
GSK announces launch of largest ever Phase III trial in lung cancer treatment

Chicago - June 5th, 2007 GlaxoSmithKline (GSK) today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC). These data were presented at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, [Abstract No: 7554]. Final trial analysis showed a 27% reduction in the relative risk of cancer recurrence following surgery in patients treated with the MAGE-A3 ASCI, compared to placebo.

Final results from this trial confirm the positive interim results released last year at ASCO 2006, and support expanded testing of this novel cancer immunotherapy, said Paul A. Bunn Jr., M.D., James Dudley Endowed Professor of Oncology, Professor of Medicine and Director of the University of Colorado Cancer Center, Aurora, Colorado. This approach represents a potentially momentous shift in the cancer treatment paradigm. I believe we have only just scratched the surface of what is possible and look forward to seeing the results of the Phase III trial in due course.

Based on these encouraging data, GSK also announced today the opening of patient recruitment to the randomized and controlled Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment. MAGE-A3 ASCI will be evaluated as adjuvant therapy in about 2,270 MAGE-A3 positive patients with completely resected stage IB, II or IIIA NSCLC.

GSKs ASCIs aim to stimulate the patients own immune response to identify and attack cancer cells in a highly specific manner. This novel cancer immunotherapy is developed using tumor specific antigens, delivered as highly purified recombinant proteins, and GSKs own proprietary Adjuvant Systems, which are specifically designed to enhance ASCIs anti-tumor activity

Phase
'"/>

Contact: Andrea Long
andreal@wagged.com
202-326-0791
GlaxoSmithKline Biologicals
5-Jun-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. AstraZeneca announces SYMBICORT is now available in the US
3. Weill Cornell Medical College announces gifts totaling $400M
4. Elsevier announces launch of Brain Stimulation
5. NSW Premier announces $15M for childrens cancer research
6. National Inventors Hall of Fame announces 2007 inductees
7. Emory University announces new Global Health Institute
8. BioMed Central announces Journal of Medical Case Reports
9. Tibotec Therapeutics announces start of largest US study on HIV treatment in women
10. Wiley announces partnership with NASPGHAN and AASLD
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/13/2018)... ... December 13, 2018 , ... ... more modern and approachable in their community. Delia Associates created a solid and ... for those dealing with substance abuse in the greater Hunterdon County area. The ...
(Date:12/13/2018)... ... ... Women’s Excellence recently implemented a new online live chat service to help ... Excellence is proud to announce that the chat service as been well-received by patients ... , “This is the second time I have used the chat. I have received ...
(Date:12/13/2018)... ... December 13, 2018 , ... ... President of Consultant Engagement. Beth brings over 20 years of leadership experience in ... Beth is passionate about building strong teams and creating vibrant cultures of personal ...
(Date:12/13/2018)... ... 2018 , ... Researchers at the Icahn School of Medicine at Mount Sinai ... rate of proliferation ever observed in adult human beta cells—the cells in the pancreas ... restores the body’s ability to produce insulin. , The finding involved one drug that ...
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... Careers at High Schools , As part of its commitment to providing more jobs ... schools , Fellow Health Partners, Inc., a New York based medical business solutions ...
Breaking Medicine News(10 mins):
(Date:12/13/2018)... ... December 13, 2018 , ... ... essential that new and established organizations, as well as top talent, have the ... risks that accompany them. , Through years of working hand-in-hand with some ...
(Date:12/13/2018)... ... 13, 2018 , ... Anxiety is the most common mental ... Thomas and BJ Goodson, anxiety-relieving wearable company The TouchPoint Solution, and the Phoenix ... stigma surrounding anxiety. Currently less than 40% receive treatment. Anxiety affects everyone differently ...
(Date:12/13/2018)... ORION, Mich. (PRWEB) , ... December 13, 2018 ... ... to accurately diagnose patients and identify the severity of their symptoms. Women’s ... for patients. , Bladder testing includes cystoscopy, urodynamic bladder testing, potassium sensitivity testing, ...
Breaking Medicine Technology:
Cached News: